Chronos Archive seal

Review checklist: Wilma Rudolph (HR-ML036)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the urgency of imaging for new focal symptoms, the steroid dose and taper, the decision against seizure prophylaxis, the WHO CNS5 integrated diagnosis, the Stupp protocol doses and monitoring, the tumor-treating fields discussion, the RANO 2.0 reading of the first post-treatment MRI, and the fall plan for a polio survivor.
provenance reviewnot_startedRecent-death rule: only what she made public, what was reported during her life, and obituaries and reference accounts: the National Women's History Museum, the U.S. Olympic & Paralympic Museum, the Tennessee Encyclopedia, Women in World History, Olympedia and the Deseret News obituary. The type and treatment of her brain cancer were never made public; everything clinical is synthetic.
safe messaging reviewnot_startedNo mental health or substance claim is made; mood screens are synthetic and below the threshold for a safety assessment. Her death is recorded once, without detail. No relative is named in the modern episode, and no health fact or decision is attributed to any real person.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. Rudolph died in 1994, so the rule applies. The case uses only what was reported publicly during her life or in obituaries and reference accounts: the Deseret News obituary, the National Women’s History Museum, the U.S. Olympic & Paralympic Museum, the Tennessee Encyclopedia, Women in World History and Olympedia. Her childhood illnesses come from these accounts and from her own published account of being told she would never walk (quoted by the museums). No sick visit is added. Her death is recorded once (CLM-0010), in plain words. No claim concerns mental health or substance use; the modern mood screens are synthetic and below the threshold for a safety assessment.
  2. What is not public. The type, location, grade and treatment of her brain cancer were never made public. Every clinical detail in the modern episode (the symptoms, the MRI, the left frontal location, glioblastoma, IDH-wildtype, MGMT methylation, the surgery, chemoradiation, tumor-treating fields, all values) is synthetic and is not a claim about her real illness. The throat cancer reported by two sources is recorded in CLM-0009 without detail and is not used in the modern episode.
  3. Choice of modern episode. Option (a), a primary brain tumor, was chosen: brain cancer is documented as her cause of death, and no source fetched describes new weakness, fatigue or pain in adult life, so post-polio syndrome (option b) has no public basis. Polio survivorship is kept in the history (PMH-003 to PMH-005), on the problem list as late effects of poliomyelitis (B91, linked to the polio claims), and in the modern frame as a factor in mobility and falls: the new right-sided weakness from the left frontal tumor adds to a left leg weakened in childhood, and each visit checks for new symptoms that could signal post-polio syndrome (none are found). The modern finding of a slightly smaller left calf is synthetic.
  4. Glioblastoma rather than another tumor. A primary brain tumor in a woman of 54 is most often glioblastoma, and glioblastoma teaches the full WHO CNS5 integrated diagnosis and the Stupp protocol. MGMT promoter methylation and a gross total resection were chosen so that the course teaches standard treatment, tumor-treating fields and the first post-treatment MRI without progression; the record ends during adjuvant cycle 1, before her real death, and implies nothing about the course of her real illness.
  5. Real people. No relative is named in the modern episode, and no decision, statement or health fact is attributed to a relative. Her mother appears only in the documented history (the bus trips to Nashville and her own published words about her mother), and in CLM-0009, which follows the Tennessee Encyclopedia in dating the diagnosis to shortly after her mother’s death without any health fact about her mother. Her four children are mentioned in the modern social history only as “four grown children” (the obituary says she was survived by two sons and two daughters). The modern family history is left empty. Other athletes, coaches and officials named in the sources are not used.
  6. Conflicts. (1) Birthplace: Saint Bethlehem (Olympedia, the U.S. Olympic & Paralympic Museum, the National Women’s History Museum) or Clarksville (the Tennessee Encyclopedia, the Deseret News); Saint Bethlehem is a community near Clarksville, and CLM-0001 gives both. (2) Age at polio: “as an infant” (Olympedia), about four (the museum, with pneumonia and scarlet fever at four) or five (secondary accounts not used); CLM-0004 states the range. (3) The brace: worn from six to ten (Tennessee Encyclopedia), taken off in public at 9½ and returned by 12 (Women in World History), braces that kept her from walking until about nine (Deseret News), and running by eleven (the museum); CLM-0006 records the range, and the past medical history says she walked without the brace by about twelve. (4) Length and frequency of the Meharry treatment: weekly for several years (Women in World History), weekly (the museum); other figures in secondary sites (twice a week, two years) are not used. (5) Cancer: brain cancer in every source; “brain and throat cancer” in the Tennessee Encyclopedia and the museum; Wikipedia states a diagnosis in July 1994 without a citation, and a search summary attributed that date to a relative quoted in The New York Times, so the month is not used and the diagnosis is dated only to 1994. (6) Why the family went to Nashville: the museum says it was the closest place with doctors who would treat her in the segregated South; no source fetched states that a Clarksville hospital refused her, so CLM-0005 uses the museum’s wording.
  7. Sources not used. The New York Times obituary (Litsky, November 13, 1994) and Britannica returned access errors and are not cited; a copy of the Times obituary hosted by a third party was not read. Her 1977 autobiography Wilma was not available; it is used only through the museums’ quotation of it, and its title and year are not stated as a claim. The Tennessee State Library and Archives was searched without finding a page on her medical history.
  8. Index age and dates. The index visit on June 29, 2026 maps to June 29, 1994, six days after her 54th birthday and before the 1994 diagnosis, which the sources date to shortly after her mother’s death. The synthetic date of birth is June 23, 1972 (shift 32 years). The chronic-care visits on July 2, July 29, September 14 and October 9, 2026, the surgery on July 8, radiotherapy from August 3 to September 11, and the preventive visit on October 29, 2026 (age 54, so a periodic adult preventive visit) map to the same days of 1994, before her death on November 12. The presenting-problem pattern is used: the symptoms are a resolved problem (R29.818) when the MRI shows a mass at visit 2; the mass is a resolved problem (D49.6) when the pathology gives the diagnosis at visit 3; glioblastoma (C71.1) is recorded at visit 3. The claims about her diagnosis and death are linked to the November 1994 timeline event, so the intake documents do not show them.
  9. Equity. As a child she was taken by bus to Nashville, a 90-minute round trip, for care at a historically Black medical school, because no closer doctor would treat her in the segregated South. The modern episode does not invent statistics about disparities in brain tumor care; it models prompt imaging, specialist review within three days, complete access to mapping surgery, molecular testing, tumor-treating fields and trial screening, and plain explanation. Her own published account of being told as a child that she would never walk is used, with care, for her wish to be told the facts plainly.
  10. Synthetic clinical picture and teaching points. Dexamethasone is started only for edema causing symptoms and tapered off within five weeks of surgery, with steroid-induced hyperglycemia (R73.9) that resolves after the taper. No prophylactic antiseizure drug is given because she never has a seizure. Hospital thrombosis prophylaxis is given after surgery, with no routine prophylaxis at home. Temozolomide is given for 42 days (the label’s 42 to 49), continuing to the Sunday after the last radiotherapy fraction. Lymphopenia from temozolomide (D72.810) keeps Pneumocystis prophylaxis going. She chooses tumor-treating fields at the end of chemoradiation and starts them with adjuvant cycle 1. Early palliative care is referred at the end of chemoradiation and seen two weeks later. Qualitative results (pathology, molecular markers, MRI, CT, hepatitis and HIV serology) appear only in procedure and note text. Height (180 cm) and weights are synthetic.
  11. Preventive visit. A periodic adult preventive visit at 54 (CPT 99396 with 99497 in plain text) on day 21 of adjuvant cycle 1, with the day-22 blood count drawn a day early. Judgment calls: breast, cervical and colorectal screening shown as up to date (synthetic), with the next rounds to be decided with her in light of her illness; lipid screening declined by her for now; bone density not indicated at 54 after under two months of dexamethasone without a fracture; inactivated influenza vaccine, PCV20 and recombinant zoster dose 1 given during chemotherapy, with no live vaccines; COVID-19 vaccine due at her pharmacy (no product code recorded). Advance care planning records only her general preferences and an unnamed agent.
  12. Focused visits. The four chronic-care follow-ups (three days with the MRI and consultation, three weeks after surgery, the end of chemoradiation, and day 1 of adjuvant temozolomide) are documented as focused visits on the NCCN CNS cancers guideline, the EANO 2021 diffuse glioma guideline, the ASCO-SNO guideline, WHO CNS5, the Stupp and EF-14 trials, the temozolomide label, RANO 2.0, the SNO-EANO seizure guideline, the ASCO thrombosis and palliative care guidelines, the EFNS post-polio guideline and the CMID depression monograph. Two deviations are recorded instead of invented results: (1) the weekly blood count in week 6 of chemoradiation was not drawn because the standing order fell on a holiday Monday and was not moved; no harm resulted (counts a week later were above the thresholds for stopping temozolomide, with no bleeding or fever), and standing orders were tied to treatment days; (2) the liver tests the label calls for midway through the first adjuvant cycle were planned, to spare her a trip, for the day-21 draw about a week late; they were normal (ALT 33, AST 29 U/L). Synthetic findings introduced: steroid leukocytosis and hyperglycemia, grade 1 thrombocytopenia, grade 2 lymphopenia and a grade 1 transaminase rise at the end of chemoradiation, grade 1 radiation dermatitis, and grade 1 scalp redness under the tumor-treating fields arrays.
  13. Consultation. The neuro-oncology referral, written at intake when only the symptoms and examination were known, and the consultation by Tomasz Brzezinski, MD (a fictional consultant), with the neurosurgery team on the day of the three-day visit, are S. The consultant answers the five referral questions in line with what the record shows afterwards: functional MRI and awake craniotomy with mapping for maximal safe resection, an MRI within 48 hours, the integrated WHO CNS5 diagnosis with MGMT, radiotherapy with temozolomide and then adjuvant temozolomide with tumor-treating fields, steroid taper, no seizure prophylaxis, hospital thrombosis prophylaxis, and the monitoring primary care shares.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-09-14
Progress note 04 (C-CDA)
Blood count in week 6 of concurrent treatmentWeekly during concurrent temozolomideA deviation: not drawn in the last week of radiotherapy because the clinic's standing order was set for the Monday, a holiday that week, and was not moved. No harm resulted: today's count, a week later, shows platelets 112 and neutrophils 2.4, above the levels that would have stopped temozolomide, and she had no bleeding or fever. Corrective action: today's count; future standing orders are tied to treatment days, not a weekday
2026-10-09
Progress note 05 (C-CDA)
Liver tests midway through adjuvant cycle 1Midway through the first cycleA planned deviation: to spare her an extra trip, the mid-cycle liver tests will be drawn with the day-22 blood count, about a week after the label's midpoint. Today's liver tests are normal after a grade 1 rise. Outcome and action to be recorded at that draw

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-07-02
Progress note 02 (C-CDA)
ImagingFunctional MRI with tractographyOrderedIn four days
2026-07-29
Progress note 03 (C-CDA)
LaboratoryHepatitis B, hepatitis C and HIV screeningOrderedDrawn today
2026-07-29
Progress note 03 (C-CDA)
Medication safetyPneumocystis pneumonia prophylaxisOrderedSulfamethoxazole-trimethoprim three times a week from the first day
2026-07-29
Progress note 03 (C-CDA)
Medication safetyAntiemetic before temozolomideOrderedOndansetron 30 to 60 minutes before the bedtime dose, on an empty stomach
2026-09-14
Progress note 04 (C-CDA)
ImagingMRI of the brain after chemoradiationOrderedIn about three weeks; enhancement in the first three months may be treatment effect (pseudoprogression) and is read by RANO 2.0
2026-09-14
Progress note 04 (C-CDA)
ReferralPalliative careReferredOutpatient consultation booked in two weeks

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-07-02White cell count11.8 10*3/uL (high)High
2026-07-02Glucose138 mg/dL (high)High
2026-07-29Glucose168 mg/dL (high)High
2026-09-14Hemoglobin11.9 g/dL (low)Low
2026-09-14White cell count3.6 10*3/uL (low)Low
2026-09-14Absolute lymphocyte count0.5 10*3/uL (low)Low
2026-09-14Platelets112 10*3/uL (low)Low
2026-09-14ALT48 U/L (high)High
2026-09-14AST39 U/L (high)High
2026-10-09Absolute lymphocyte count0.6 10*3/uL (low)Low
2026-10-29Hemoglobin11.8 g/dL (low)Low
2026-10-29White cell count3.4 10*3/uL (low)Low
2026-10-29Absolute lymphocyte count0.6 10*3/uL (low)Low
2026-10-29Platelets121 10*3/uL (low)Low